Literature DB >> 25675353

Relationships between preptin and osteocalcin in obese, overweight, and normal weight adults.

Mervat El-Eshmawy1, Ibrahim Abdel Aal.   

Abstract

Preptin is an endocrine peptide secreted from pancreatic β cells; it acts as a physiological amplifier of glucose-mediated insulin secretion. Osteocalcin, secreted by osteoblasts, is also involved in the regulation of body energy in that it modulates fat and glucose metabolism. The aim of this study was to investigate circulating preptin and osteocalcin levels and the possible association between them in obese and overweight adults. A total of 100 obese-overweight adults and 50 healthy controls matched for age and sex were enrolled in this study. Anthropometric measurements were taken and fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profile, preptin, and osteocalcin were assessed. Preptin was significantly higher in obese and overweight subjects than in controls, whereas osteocalcin was significantly lower. In multiple regression analysis, preptin was independently influenced by waist circumference (WC) (β = 3.75, P = 0.03), fasting insulin (β = 4.77, P = 0.01), HOMA-IR (β = 8.21, P = 0.003), and osteocalcin (β = -28.41, P = 0.04). Osteocalcin was independently influenced by body mass index (β = -1.46, P = 0.05), WC (β = -2.04, P = 0.03), fasting insulin (β = -2.69, P = 0.02), HOMA-IR (β = -0.19, P = 0.006), and triglyceride (β = -4.54, P = 0.001). In conclusion, elevated serum preptin and decreased osteocalcin concentrations, together with insulin resistance, are associated with obesity and overweight. Serum preptin is also independently associated with osteocalcin, which may explain, at least in part, the crosstalk between bone and the β cells of the pancreas.

Entities:  

Keywords:  obesity–overweight; obésité/surpoids; osteocalcin; ostéocalcine; preptin; preptine

Mesh:

Substances:

Year:  2015        PMID: 25675353     DOI: 10.1139/apnm-2014-0338

Source DB:  PubMed          Journal:  Appl Physiol Nutr Metab        ISSN: 1715-5312            Impact factor:   2.665


  7 in total

1.  Investigation of the relation between bone mass density and serum preptin levels in pre- and postmenopausal women.

Authors:  Saeed Nazari Soltan Aahmad; Sajjad Nourollahi; Faranak Kazerouni; Nahid Kianmehr; Hamed Hajipour; Davoud Sanajou; Vahid Hosseini
Journal:  J Bone Miner Metab       Date:  2017-11-13       Impact factor: 2.626

2.  Searching for additional endocrine functions of the skeleton: genetic approaches and implications for therapeutics.

Authors:  Jianwen Wei; Stephen Flaherty; Gerard Karsenty
Journal:  Expert Rev Endocrinol Metab       Date:  2015-06-16

Review 3.  Association between serum osteocalcin and body mass index: a systematic review and meta-analysis.

Authors:  Hamed Kord-Varkaneh; Kurosh Djafarian; Masoud Khorshidi; Sakineh Shab-Bidar
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

4.  Serum Irisin, Adropin, and Preptin in Obese Patients 6 Months After Bariatric Surgery.

Authors:  M Glück; J Glück; M Wiewióra; B Rogala; J Piecuch
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

Review 5.  Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives.

Authors:  Irene Traghella; Francesca Mastorci; Alessia Pepe; Alessandro Pingitore; Cristina Vassalle
Journal:  Biomolecules       Date:  2018-06-15

6.  Is Preptin a New Bone Metabolism Parameter in Hemodialysis Patients?

Authors:  Małgorzata Kałużna; Krzysztof Pawlaczyk; Krzysztof Schwermer; Krzysztof Hoppe; Aisha Yusuf Ibrahim; Magdalena Czlapka-Matyasik; Elżbieta Wrotkowska; Katarzyna Ziemnicka; Andrzej Oko; Marek Ruchała
Journal:  Life (Basel)       Date:  2021-04-12

7.  Association between obesity and risk of fracture, bone mineral density and bone quality in adults: A systematic review and meta-analysis.

Authors:  Anne-Frédérique Turcotte; Sarah O'Connor; Suzanne N Morin; Jenna C Gibbs; Bettina M Willie; Sonia Jean; Claudia Gagnon
Journal:  PLoS One       Date:  2021-06-08       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.